RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas
about
FAK in cancer: mechanistic findings and clinical applicationsTargeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKThe impact of the Cancer Genome Atlas on lung cancer.Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung CancerNullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis.Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancerFAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.Diet-induced unresolved ER stress hinders KRAS-driven lung tumorigenesis.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Loss of RhoA Exacerbates, Rather Than Dampens, Oncogenic K-Ras Induced Lung Adenoma Formation in Mice.Focal adhesion kinase-promoted tumor glucose metabolism is associated with a shift of mitochondrial respiration to glycolysis.FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β.KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Eukaryotic Translation Initiation Factor 5A (EIF5A) Regulates Pancreatic Cancer Metastasis by Modulating RhoA and Rho-associated Kinase (ROCK) Protein Expression LevelsClinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort.A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.PIAS1 Promotes Lymphomagenesis through MYC UpregulationTargeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung TumorigenesisA non-canonical role for Rgnef in promoting integrin-stimulated focal adhesion kinase activation.KCNMA1 cooperating with PTK2 is a novel tumor suppressor in gastric cancer and is associated with disease outcome.Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma.RhoGEFs in cell motility: novel links between Rgnef and focal adhesion kinase.New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway.Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3Rho GTPases: Anti- or pro-neoplastic targets?Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.Human embryonic and induced pluripotent stem cells maintain phenotype but alter their metabolism after exposure to ROCK inhibitor.Contextual tumor suppressor function of T cell death-associated gene 8 (TDAG8) in hematological malignancies.PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer.Somatic Mutations and Splicing Variants of Focal Adhesion Kinase in Non-Small Cell Lung Cancer.Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK.Polypharmacology-based ceritinib repurposing using integrated functional proteomics.KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.
P2860
Q27026533-BF6A1A2C-0201-420B-8804-0A3244924584Q28083446-9516B02C-1399-4E97-AB4C-033D7B7C37FDQ28084190-50D78413-B32C-4E4C-8920-D6F07660F13FQ28550689-31D0995D-14A4-4816-8699-241BF1C4D7EDQ33758232-F64CECAD-8518-4060-BA08-F54EC371B7C7Q33787214-A830BD2C-55BE-481C-B298-795D06F21EBBQ34021043-4F2B254D-E57D-401E-B855-DCFA21546D87Q35008552-28DC5401-26C7-41D3-A2D8-DA3A2A0F9702Q35136424-5197EC1A-6836-4571-93B4-E95FF0361305Q35648144-F98D2646-317E-4BCD-9360-123C21E37C64Q35800385-EA69EC08-EC04-4CB7-A42C-3A992594A031Q36023053-BCEBF3B7-82D2-4F5D-95C0-8CBD0DFFA8CFQ36369197-E4E8D4BE-53E8-4DCB-9C90-7FC18A021D71Q36398735-230842AB-8CEB-4D50-B7D5-D5B082FDAC4BQ36444280-4C924077-D322-4A0F-A90E-1795C8B5C683Q36475722-1FCAD334-0789-47DA-98AE-522D88CF333AQ36834559-DEADCD3A-B972-489E-90DA-B95959E273CCQ36984471-7784E557-D905-4E4F-B32C-2FE89BCA8319Q37072889-63770944-07CC-4456-AFA6-ECF7719C52E8Q37100734-B2B30E8E-C403-4890-B84C-7873F2DA7AB5Q37168327-39A897D7-03FD-4653-9DB9-E793028D7E51Q37287392-52C5AAED-D5A1-4DF7-83BC-CF2FBB585B10Q37663367-EF4EE537-53B3-483F-8F3C-4805615E2269Q37677409-254C31E0-6802-4983-BDD4-8D75571EB01AQ38182132-907C03C1-FE69-420D-98F8-167A4B450B5AQ38604713-42FE6641-A890-4C79-AF57-3F6CB7B6B3E4Q38622790-404AD08B-0212-4AEF-814B-D14E2B936A95Q38669282-C50F9A9B-910A-4A71-A86D-63BFA980FB83Q38742653-FA9515F0-08A2-4ACD-BD62-69AA37448371Q38780866-620028A3-ED7B-4253-85BC-E99DE6A29583Q38825099-DCA431F4-0169-4545-BD81-856ECCE836FBQ39178061-0F8D7A96-2C30-40BF-AC57-E24B4E468170Q41913041-67057CDD-A42D-41A4-9915-D01DCB02A7F2Q42374132-46B5E6C0-FF21-4262-9E41-969C3F36D1D7Q42493887-4EC2FB53-35C8-4FB4-A80E-48B85080D0E1Q42778341-7F17DC51-60D2-4EA7-9E19-5B92EA7DD9BDQ44951464-F591457B-5950-4C08-A49E-4CEDA6219C1FQ45067787-A9C767E2-35D8-4AFF-B590-A2DCCB6F2B7CQ47678215-832CB76F-A906-4BA3-9C99-534AE21C6DBFQ49887897-A3182317-008B-44BE-B8AD-4905FC042C3C
P2860
RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
RHOA-FAK is a required signali ...... AS-driven lung adenocarcinomas
@ast
RHOA-FAK is a required signali ...... AS-driven lung adenocarcinomas
@en
type
label
RHOA-FAK is a required signali ...... AS-driven lung adenocarcinomas
@ast
RHOA-FAK is a required signali ...... AS-driven lung adenocarcinomas
@en
prefLabel
RHOA-FAK is a required signali ...... AS-driven lung adenocarcinomas
@ast
RHOA-FAK is a required signali ...... AS-driven lung adenocarcinomas
@en
P2093
P2860
P1433
P1476
RHOA-FAK is a required signali ...... AS-driven lung adenocarcinomas
@en
P2093
Adriana Heguy
Carmen Behrens
Francesca Torti
Georgia Konstantinidou
Giorgio Ramadori
Kim Kangasniemi
Michael T Dellinger
Pier Paolo Scaglioni
Rachel E Ramirez
Rolf A Brekken
P2860
P304
P356
10.1158/2159-8290.CD-12-0388
P577
2013-01-28T00:00:00Z